Characterizing respiratory exacerbations in primary ciliary dyskinesia
原发性纤毛运动障碍呼吸加重的特征
基本信息
- 批准号:10754387
- 负责人:
- 金额:$ 19.69万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-07-01 至 2024-06-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
ABSTRACT
Primary ciliary dyskinesia (PCD) is a rare, genetically heterogeneous, orphan disease characterized by pro-
gressive upper and lower respiratory tract infections and inflammation. Similar to other suppurative lung dis-
eases, people with primary ciliary dyskinesia experience episodic, acute respiratory exacerbations, clinically
characterized by increasing productive cough, fever and fatigue, that are typically treated with antibiotics and
increased airway clearance. Acute respiratory exacerbations cause significant morbidity and substantial health
care utilization, school or work absenteeism, and in some suppurative airway diseases accelerate structural
airway damage and airway obstruction. Given their negative impact on the lives of people with primary ciliary
dyskinesia, exacerbations have been targets for interventional trials designed to establish evidence-based guide-
lines for their prevention and treatment. However, the infectious precipitants that likely cause acute respiratory
exacerbations are frequently undefined and could be important factors for clinical trials. This ancillary study will
involve subjects with primary ciliary dyskinesia already enrolled in an NIH-funded parent longitudinal study
RDCRN Protocol 5907) that is designed to define the key characteristics of respiratory exacerbations and eval-
uate potential predictors and time to first exacerbations. The first Specific Aim will examine molecular approaches
to detection of viruses and bacteria in patients with PCD to define the baseline microbial state and the microbial
phenotype of respiratory exacerbations, using assays that can be performed on self-collected samples obtained
in the home, which will test two complementary hypotheses, that the microbial phenotype of a baseline sputum
sample can predict the frequency and severity of acute respiratory tract illnesses, and the microbial phenotype
of a sputum sample obtained during an ARI can predict the severity of the episode. In the second Aim 2, we will
use nasal gene expression profiles to characterize host response to acute respiratory tract illnesses, testing the
hypothesis that assessment of the host response will distinguish between viral infections with and without clinical
manifestations. This ancillary study that will enhance the parent project by further refining the characterization of
respiratory tract exacerbations, and establish the feasibility of microbial phenotyping of subjects at baseline and
during exacerbations on respiratory samples collected at home. We will examine the feasibility of microbial phe-
notyping of subjects at baseline and during exacerbations, thus determining the role of infectious precipitants
and inflammatory responses during respiratory tract exacerbations. Specifically, it will provide a highly detailed
characterization of the bacteria and viruses causing acute exacerbations in the PCD population, providing pilot
data that will better define respiratory tract exacerbations as a key endpoint for future clinical trials.
抽象的
原发性纤毛运动障碍 (PCD) 是一种罕见的、遗传异质性的孤儿疾病,其特征是
进行性上呼吸道和下呼吸道感染和炎症。与其他化脓性肺疾病相似
临床上,患有原发性纤毛运动障碍的人会经历阵发性急性呼吸道症状加重
其特点是咳嗽增多、发烧和疲劳,通常用抗生素和
增加气道间隙。急性呼吸系统恶化会导致严重的发病率和严重的健康问题
护理利用、学校或工作缺勤以及某些化脓性气道疾病加速结构性
气道损伤和气道阻塞。鉴于它们对原发性睫状体患者的生活产生负面影响
运动障碍、病情加重已成为干预试验的目标,旨在建立基于证据的指导
预防和治疗的路线。然而,可能引起急性呼吸道疾病的传染性沉淀物
病情加重通常是不确定的,可能是临床试验的重要因素。这项辅助研究将
涉及已参加 NIH 资助的家长纵向研究的原发性纤毛运动障碍受试者
RDCRN 协议 5907)旨在定义呼吸恶化的关键特征和评估
评估潜在的预测因素和首次恶化的时间。第一个具体目标将检查分子方法
检测 PCD 患者体内的病毒和细菌,以确定基线微生物状态和微生物水平
呼吸系统恶化的表型,使用可对自行收集的样本进行的检测
在家里,这将测试两个互补的假设,即基线痰的微生物表型
样本可以预测急性呼吸道疾病的频率和严重程度以及微生物表型
在 ARI 期间获得的痰样本可以预测发作的严重程度。在第二个目标 2 中,我们将
使用鼻基因表达谱来表征宿主对急性呼吸道疾病的反应,测试
假设对宿主反应的评估将区分有临床症状和无临床症状的病毒感染
表现形式。这项辅助研究将通过进一步细化特征来增强母项目
呼吸道恶化,并建立受试者基线和微生物表型分析的可行性
在病情加重期间在家收集的呼吸道样本。我们将研究微生物PH值的可行性
在基线和恶化期间对受试者进行分型,从而确定传染性诱发因素的作用
以及呼吸道恶化期间的炎症反应。具体来说,它将提供非常详细的
导致 PCD 人群急性加重的细菌和病毒的特征,提供试点
这些数据将更好地将呼吸道恶化定义为未来临床试验的关键终点。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
THOMAS W FERKOL其他文献
THOMAS W FERKOL的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('THOMAS W FERKOL', 18)}}的其他基金
Characterizing respiratory exacerbations in primary ciliary dyskinesia
原发性纤毛运动障碍呼吸加重的特征
- 批准号:
10655640 - 财政年份:2022
- 资助金额:
$ 19.69万 - 项目类别:
Pediatric Cardiovascular and Pulmonary Research Training Program
儿科心血管和肺研究培训计划
- 批准号:
9214237 - 财政年份:2015
- 资助金额:
$ 19.69万 - 项目类别:
Pediatric Cardiovascular and Pulmonary Research Training Program
儿科心血管和肺研究培训计划
- 批准号:
9393040 - 财政年份:2015
- 资助金额:
$ 19.69万 - 项目类别:
Influence of the Enteric Microbiome on the Genesis of Bronchopulmonary Dysplasia
肠道微生物组对支气管肺发育不良发生的影响
- 批准号:
8464209 - 财政年份:2010
- 资助金额:
$ 19.69万 - 项目类别:
Influence of the Enteric Microbiome on the Genesis of Bronchopulmonary Dysplasia
肠道微生物组对支气管肺发育不良发生的影响
- 批准号:
7867621 - 财政年份:2010
- 资助金额:
$ 19.69万 - 项目类别:
Influence of the Enteric Microbiome on the Genesis of Bronchopulmonary Dysplasia
肠道微生物组对支气管肺发育不良发生的影响
- 批准号:
8281487 - 财政年份:2010
- 资助金额:
$ 19.69万 - 项目类别:
Influence of the Enteric Microbiome on the Genesis of Bronchopulmonary Dysplasia
肠道微生物组对支气管肺发育不良发生的影响
- 批准号:
8068836 - 财政年份:2010
- 资助金额:
$ 19.69万 - 项目类别:
Influence of the Enteric Microbiome on the Genesis of Bronchopulmonary Dysplasia
肠道微生物组对支气管肺发育不良发生的影响
- 批准号:
8662298 - 财政年份:2010
- 资助金额:
$ 19.69万 - 项目类别:
LONGITUDINAL STUDY OF PRIMARY CILIARY DYSKINESIA (PCD STUDY)
原发性纤毛运动障碍的纵向研究(PCD 研究)
- 批准号:
7603416 - 财政年份:2007
- 资助金额:
$ 19.69万 - 项目类别:
相似国自然基金
呼吸中枢低氧通气反应的遗传机制及其对睡眠呼吸障碍的影响
- 批准号:81070069
- 批准年份:2010
- 资助金额:34.0 万元
- 项目类别:面上项目
中枢钠氢交换蛋白3在睡眠呼吸暂停呼吸控制稳定性中的作用和调控机制
- 批准号:30900646
- 批准年份:2009
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
个体化肺保护性通气对急性呼吸窘迫综合征动物模型肺、胰腺和小肠凋亡及保护功能的作用机制研究
- 批准号:30540034
- 批准年份:2005
- 资助金额:10.0 万元
- 项目类别:专项基金项目
救治呼吸衰竭新方法及脉冲放电治疗仪的研究
- 批准号:50347009
- 批准年份:2003
- 资助金额:10.0 万元
- 项目类别:专项基金项目
相似海外基金
Dose escalation clinical trial of high-dose oral montelukast to inform future RCT in children with acute asthma exacerbations
大剂量口服孟鲁司特的剂量递增临床试验为哮喘急性发作儿童的未来随机对照试验提供信息
- 批准号:
10649012 - 财政年份:2023
- 资助金额:
$ 19.69万 - 项目类别:
The nose-lung cross talk in upper respiratory virus infection induced asthma exacerbations
上呼吸道病毒感染引起的哮喘加重中的鼻肺交互作用
- 批准号:
10733754 - 财政年份:2023
- 资助金额:
$ 19.69万 - 项目类别:
Defining a gene expression signature of airway disease, COPD exacerbations, and response to treatment
定义气道疾病、COPD 恶化和治疗反应的基因表达特征
- 批准号:
10733573 - 财政年份:2023
- 资助金额:
$ 19.69万 - 项目类别:
A Mixed Methods Evaluation of Developing COPD Exacerbations in the MARC Cohort
MARC 队列中 COPD 加重的混合方法评估
- 批准号:
10605385 - 财政年份:2023
- 资助金额:
$ 19.69万 - 项目类别:
Corticosteroids for Acute Exacerbations of Idiopathic Pulmonary Fibrosis: Patterns and Outcomes
皮质类固醇治疗特发性肺纤维化急性加重:模式和结果
- 批准号:
10679224 - 财政年份:2023
- 资助金额:
$ 19.69万 - 项目类别:
Impaired Pneumococcal Antibody Function and Exacerbations of Chronic Obstructive Pulmonary Disease
肺炎球菌抗体功能受损和慢性阻塞性肺疾病恶化
- 批准号:
10543560 - 财政年份:2022
- 资助金额:
$ 19.69万 - 项目类别:
Characterizing respiratory exacerbations in primary ciliary dyskinesia
原发性纤毛运动障碍呼吸加重的特征
- 批准号:
10655640 - 财政年份:2022
- 资助金额:
$ 19.69万 - 项目类别:
Novel Markers of Treatment Responsiveness for Pediatric Acute Asthma Exacerbations
小儿哮喘急性加重治疗反应性的新标志物
- 批准号:
10850297 - 财政年份:2022
- 资助金额:
$ 19.69万 - 项目类别:
Novel Markers of Treatment Responsiveness for Pediatric Acute Asthma Exacerbations
小儿哮喘急性加重治疗反应性的新标志物
- 批准号:
10548194 - 财政年份:2022
- 资助金额:
$ 19.69万 - 项目类别:
Identifying microbiome changes that predict respiratory exacerbations in patients with non-cystic fibrosis bronchiectasis
识别预测非囊性纤维化支气管扩张患者呼吸恶化的微生物组变化
- 批准号:
475747 - 财政年份:2022
- 资助金额:
$ 19.69万 - 项目类别:
Studentship Programs